The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2020 | Harnessing apoptosis in AML
Marina Konopleva, MD, PhD, of The University of Texas MD Anderson Cancer Center, Houston, TX, outlines clinical updates evaluating the use of agents targeting apoptotic signals in acute myeloid leukemia (AML), including venetoclax, a BCL-2 inhibitor, in combination with azacitidine, as well as triplet combinations with FLT3 inhibitors or novel monoclonal antibodies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
